Health and Medicine

model of DNA double helix

New type of trial shows promise for several cancers

Anti-cancer drugs are typically tested on one type of cancer at a time. But an international consortium of cancer investigators, including Vanderbilt-Ingram Cancer Center (VICC) researchers, simultaneously tested an existing therapy in patients with several different forms of cancer that all exhibit the same tumor gene mutation.

HIV cell

Grants bolster HIV-focused research capacity

The Vanderbilt Institute for Global Health (VIGH) has received two new grants from the Fogarty International Center of the National Institutes of Health (NIH) to build HIV-focused research capacity with key partners in Zambia, Mozambique and Brazil.

brain

Study seeks to ease ‘chemobrain’ for cancer patients

Many women who receive chemotherapy for breast cancer report problems with their thinking, memory and attention after treatment.

New therapeutic target for diabetes

The factor FoxM1 increases the proliferation and function of insulin-producing beta cells, making it an attractive therapeutic target for diabetes.

Grant bolsters Clinical Data Research Network

The Mid-South Clinical Data Research Network, led by Vanderbilt University’s Russell Rothman, M.D., M.P.P., has been approved for a three-year, $8.5 million funding award from the independent Patient-Centered Outcomes Research Institute (PCORI) to expand its efforts to improve healthcare throughout the Southeast.

Macara lands award to explore cancer cell behavior

Vanderbilt’s Ian Macara, Ph.D., has won an Outstanding Investigator Award from the National Cancer Institute (NCI) — nearly $6.6 million over seven years — to support the “unusual potential” of his research, which seeks to understand and predict cancer cell “behavior.”

1 112 113 114 115 116 192